{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:31:23Z","timestamp":1765283483383,"version":"3.46.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cyto.2025.157075","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:05:40Z","timestamp":1763651140000},"page":"157075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of cytokines in immune cell-mediated multiple myeloma and the identification of therapeutic targets"],"prefix":"10.1016","volume":"197","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.157075_bb0005","first-page":"3","article-title":"Epidemiology, staging, and Management of Multiple Myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.cyto.2025.157075_bb0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2025.157075_bb0015","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cyto.2025.157075_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663748","article-title":"Predictive role of immune profiling for survival of multiple myeloma patients","volume":"12","author":"Zhaoyun","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157075_bb0025","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2025.157075_bb0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cyto.2025.157075_bb0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.14185","article-title":"Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose","volume":"86","author":"Westerdijk","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157075_bb0040","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1038\/s41598-020-62088-7","article-title":"Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells","volume":"10","author":"Rausch","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157075_bb0045","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.3390\/ijms23094694","article-title":"Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia","volume":"23","author":"Katagiri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157075_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107128","article-title":"Sunitinib malate inhibits intestinal tumor development in male ApcMin\/+ mice by down-regulating inflammation-related factors with suppressing \u03b2-cateinin\/c-Myc pathway and re-balancing Bcl-6 and Caspase-3","volume":"90","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2025.157075_bb0055","series-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"eLife 7","author":"Hemani","year":"2018"},{"key":"10.1016\/j.cyto.2025.157075_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.cyto.2025.157075_bb0065","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2025.157075_bb0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2025.157075_bb0075","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-023-01588-w","article-title":"Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets","volume":"24","author":"Zhao","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2025.157075_bb0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.cyto.2025.157075_bb0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.157075_bb0090","article-title":"The role of immune cell signatures in the pathogenesis of ovarian-related diseases: a causal inference based on mendelian randomization","author":"Lu","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.cyto.2025.157075_bb0095","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"CRP CHD genetics collaboration, avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.cyto.2025.157075_bb0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.cyto.2025.157075_bb0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jclinepi.2014.09.005","article-title":"Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy","volume":"68","author":"Cohen","year":"2015","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.cyto.2025.157075_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.cyto.2025.157075_bb0115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2025.157075_bb0120","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.cyto.2025.157075_bb0125","doi-asserted-by":"crossref","DOI":"10.1515\/ijb-2015-0074","article-title":"Mendelian randomization using public data from genetic consortia, the","volume":"12","author":"Thompson","year":"2016","journal-title":"Int. J. Biostat."},{"key":"10.1016\/j.cyto.2025.157075_bb0130","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/bioinformatics\/btz749","article-title":"Bayesian weighted Mendelian randomization for causal inference based on summary statistics","volume":"36","author":"Zhao","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cyto.2025.157075_bb0135","article-title":"Orienting the causal relationship between imprecisely measured traits using GWAS summary data","volume":"13","author":"Hemani","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cyto.2025.157075_bb0140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng.3538","article-title":"Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets","volume":"48","author":"Zhu","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2025.157075_bb0145","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2025.157075_bb0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm1766","article-title":"Activation of c-kit in dendritic cells regulates T helper cell differentiation and allergic asthma","volume":"14","author":"Krishnamoorthy","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2025.157075_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/925135","article-title":"CD4+T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.cyto.2025.157075_bb0160","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/bloodadvances.2020001434","article-title":"CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages","volume":"4","author":"Haabeth","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.cyto.2025.157075_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an eastern cooperative oncology group phase 3 trial for newly diagnosed multiple myeloma patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.157075_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1174138","article-title":"SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy","volume":"14","author":"Farhangnia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157075_bb0175","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2007.11.005","article-title":"Consequence of the SLAM-SAP signaling pathway in innate-like and conventional lymphocytes","volume":"27","author":"Veillette","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2025.157075_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157075_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/cancers13020279","article-title":"Immune functions of signaling lymphocytic activation molecule family molecules in multiple myeloma","volume":"13","author":"Ishibashi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cyto.2025.157075_bb0190","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating multiple myeloma in the context of the Bone marrow microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cyto.2025.157075_bb0195","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cyto.2025.157075_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cyto.2025.157075_bb0205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.cyto.2025.157075_bb0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044276","article-title":"Exploring multiple myeloma pathobiology and immune cell signatures: evidence from bidirectional genetic analysis","volume":"104","author":"Tian","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cyto.2025.157075_bb0215","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-kit) inhibitors: a potential therapeutic target in cancer cells","volume":"10","author":"Abbaspour Babaei","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.cyto.2025.157075_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12916-021-02193-0","article-title":"The PRACTICAL consortium, BPC3, circulating inflammatory cytokines and risk of five cancers: a mendelian randomization analysis","volume":"20","author":"Bouras","year":"2022","journal-title":"BMC Med."},{"year":"2024","series-title":"Association between Circulating Inflammatory Markers and Adult cancer Risk: A Mendelian Randomization Analysis, eBioMedicine 100","author":"Yarmolinsky","key":"10.1016\/j.cyto.2025.157075_bb0225"},{"key":"10.1016\/j.cyto.2025.157075_bb0230","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2025.157075_bb0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-025-01277-x","article-title":"Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy","volume":"15","author":"Beer","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cyto.2025.157075_bb0240","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.cyto.2025.157075_bb0245","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157075_bb0250","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2025.157075_bb0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cyto.2025.157075_bb0260","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3324\/haematol.12171","article-title":"Expression of c-kit isoforms in multiple myeloma: differences in signaling and drug sensitivity","volume":"93","author":"Montero","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cyto.2025.157075_bb0265","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1182\/blood.V114.22.4954.4954","article-title":"A phase II trial of sunitinib (SU11248) in multiple myeloma","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.157075_bb0270","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2025.157075_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:26:31Z","timestamp":1765283191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"alternative-id":["S1043466625002224"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157075","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of cytokines in immune cell-mediated multiple myeloma and the identification of therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157075"}}